Drugs / Guilingji
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03647384 | Aug 2018 → Dec 2019 | cognitive disorder | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Guilingji | “The purpose of this study is to evaluate the safety and efficacy of Guilingji Capsules (GLJC, ) in treating mild-to-moderate CI with Shen (Kidney) and marrow deficiency syndrome.” PMID 32761337 ↗ Aug 2020 |
| Known as | GLJC | “The purpose of this study is to evaluate the safety and efficacy of Guilingji Capsules (GLJC, ) in treating mild-to-moderate CI with Shen (Kidney) and marrow deficiency syndrome.” PMID 32761337 ↗ Aug 2020 |
| Known as | Guilingji Capsules | “The purpose of this study is to evaluate the safety and efficacy of Guilingji Capsules (GLJC, ) in treating mild-to-moderate CI with Shen (Kidney) and marrow deficiency syndrome.” PMID 32761337 ↗ Aug 2020 |